FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 7,706 other subscribers

Archives

Posts Tagged ‘pancreatic cancer’

May 7, 2019

Anti-vaccine Hype is a Threat to People with Cancer

Cancer treatment is challenging enough, without the added threat of a measles outbreak caused by decreased vaccinations.

January 31, 2019

Highlights from the 2018 Joining FORCEs Conference

Our Joining FORCEs conference informs, inspires and supports the hereditary cancer community. Judging from the feedback, last year’s October conference (our 11th!) once again successfully hit the mark. More than 700 people from the U.S. and other countries traveled to San Diego looking for more answers, deeper understanding, a stronger sense of community, clarity on … + read more

November 28, 2018

You Don’t Need a Family History of Cancer to Benefit from Genetic Testing

by Sue Friedman Many people mistakenly believe that genetic testing for inherited mutations in BRCA1, BRCA2, Lynch Syndrome, and other genes is only appropriate for people with many cases of cancer in their family. National guidelines—based on the latest research—state otherwise. There are situations where a single case of cancer in a family is enough … + read more

June 17, 2018

Solving for Y: Reaching Men About Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, Prostate And Related Cancers (HBOC)

by Sue Friedman Half of all people with an inherited BRCA, ATM, CHEK2, PALB2 or other mutation associated with HBOC are men. Nevertheless, the majority of awareness, research, and resources have focused on genetic testing in women. A recent article in JAMA highlights this disparity in BRCA testing between men and women. Emerging information on … + read more

May 30, 2018

Where’s FORCE? March and April

by Lisa Schlager “Where’s FORCE” highlights the ongoing efforts of FORCE staff and volunteers on behalf of the community. March As a member of the Bayer Oncology Patient Advocacy Advisory Council (PAAC), FORCE Vice President of Public Policy Lisa Schlager joined representatives from other advocacy groups and Bayer to review project proposals submitted by nonprofit … + read more

April 12, 2018

PARP Inhibitors and Hereditary Cancer: What’s New?

by Sue Friedman PARP inhibitors are drugs designed specifically to treat cancers in people with certain inherited mutations, including BRCA1 and BRCA2, among others. These drugs block an enzyme – known as PARP – used by cells to repair damage to their DNA. Although these agents seem to be most effective in people with mutations—not just … + read more

November 14, 2016

Voices of FORCE: A BRCA Mutation is a Factor in Pancreatic Cancer

By Rona Greenberg Hereditary breast and ovarian cancer is part of my family history. My grandmother, Rebecca, for whom I am named, died from breast/ovarian cancer in1934; my mother was ten years old. My mother died from the same cancer in 1967; I was nineteen years old with three younger sisters. In 1997, I was … + read more

November 1, 2016

Learn About Hereditary Pancreatic Cancer

by Lisa Rezende, PhD November is Pancreatic Cancer Awareness Month. FORCE wants to raise awareness of the risk of pancreatic cancer in the hereditary cancer community. Pancreatic cancer is rare but BRCA carriers have a high risk, up to 5% compared to the 1.5% for the general population. Between BRCA carriers, the risk is higher … + read more

May 27, 2016

Blog: What Do the New Guidelines from the National Comprehensive Cancer Network Mean For You?

by Lisa Rezende, PhD People with hereditary cancer face many decisions, such as whether or not to have genetic testing, choosing the best type and frequency of cancer screening, and whether or not to manage cancer risk through surgery. Health care providers look to national guidelines to give their patients advice as they make these … + read more

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

March 30, 2016

Update on Pancreatic Cancer Genetics Research

By Talia Golan, MD and Sue Friedman, DVM BRCA and pancreatic cancer The link between breast and ovarian cancer and BRCA mutations has been known since the 1990s. However, the awareness that these mutations also increase pancreatic cancer risk is more recent. If all patients with pancreatic cancer were tested for a BRCA1 or BRCA2 … + read more

January 8, 2016

Value in Cancer Care: Including Consumers in the Dialogue

by Lisa Schlager, Vice President of Policy and Community Affairs Value and access to appropriate health care is of vital importance to patients and their families, particularly as cancer diagnoses continue to rise—up more than 20 percent in the past decade—and health care costs steadily increase. In this environment, more attention is being paid to … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered